Skip to main content
. 2017 Jul 27;8(43):73372–73386. doi: 10.18632/oncotarget.19637

Figure 5. Blocking aberrant LSD1 affects expression of CTGF, LOXL4 and MMP13 in a pre-existing tonsillar OSCC patient-derived xenograft model (PDX).

Figure 5

A. GSK-LSD1 injection inhibits the growth of pre-existing tumors as detected at 32 weeks in a tonsillar OSCC PDX model (n = 10 per condition). Statistical analyses were performed with unpaired Student’s t-tests. * P-value<0.05. B. Caliper measurements of tumor volumes; C. GSK-LSD1 reduced the mRNA expression levels of CTGF, MMP13, LOXL4, and Vimentin expression; D. GSK-LSD1 increased the expression of E-cadherin and E. Relative to vehicle injection, GSK-LSD1 injection inhibits CTGF expression in pre-existing tonsillar OSCC PDX tissue sections. Statistical analyses were performed with unpaired Student’s t-tests. * P-value<0.05.